126 related articles for article (PubMed ID: 38719422)
1. ERBB2 Amplification in NSCLC: How Many Faces?
Shih JY
J Thorac Oncol; 2024 May; 19(5):668-670. PubMed ID: 38719422
[No Abstract] [Full Text] [Related]
2. Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC.
Odintsov I; Makarem M; Nishino M; Bachert SE; Zhang T; LoPiccolo J; Paweletz CP; Gokhale PC; Ivanova E; Saldanha A; Rudin CM; Lockwood WW; Ladanyi M; Somwar R; Jänne PA; Sholl LM
J Thorac Oncol; 2024 May; 19(5):732-748. PubMed ID: 38154514
[TBL] [Abstract][Full Text] [Related]
3. Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.
Saigi M; McLeer-Florin A; Pros E; Nadal E; Brambilla E; Sanchez-Cespedes M
Clin Transl Oncol; 2018 Jul; 20(7):881-888. PubMed ID: 29139039
[TBL] [Abstract][Full Text] [Related]
4. Ploidy, expression of erbB1, erbB2, P53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer.
Reinmuth N; Brandt B; Kunze WP; Junker K; Thomas M; Achatzy R; Scheld HH; Semik M
Eur Respir J; 2000 Nov; 16(5):991-6. PubMed ID: 11153605
[TBL] [Abstract][Full Text] [Related]
5. Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung.
Pelosi G; Del Curto B; Dell'Orto P; Pasini F; Veronesi G; Spaggiari L; Maisonneuve P; Iannucci A; Terzi A; Lonardoni A; Viale G
Int J Cancer; 2005 Jan; 113(1):101-8. PubMed ID: 15386424
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-331-3p inhibits epithelial-mesenchymal transition by targeting ErbB2 and VAV2 through the Rac1/PAK1/β-catenin axis in non-small-cell lung cancer.
Li X; Zhu J; Liu Y; Duan C; Chang R; Zhang C
Cancer Sci; 2019 Jun; 110(6):1883-1896. PubMed ID: 30955235
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
Patil T; Mushtaq R; Marsh S; Azelby C; Pujara M; Davies KD; Aisner DL; Purcell WT; Schenk EL; Pacheco JM; Bunn PA; Camidge DR; Doebele RC
Clin Lung Cancer; 2020 May; 21(3):e191-e204. PubMed ID: 31859066
[TBL] [Abstract][Full Text] [Related]
8. p95HER2 truncated form in resected non-small cell lung cancer.
Cappuzzo F; Cho YG; Sacconi A; Alì G; Siclari O; Incarbone M; Destro A; Terracciano L; Fontanini G; Marchetti A; Roncalli M; Varella-Garcia M
J Thorac Oncol; 2012 Mar; 7(3):520-7. PubMed ID: 22307009
[TBL] [Abstract][Full Text] [Related]
9. Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study.
Hirashima N; Takahashi W; Yoshii S; Yamane T; Ooi A
Mod Pathol; 2001 Jun; 14(6):556-62. PubMed ID: 11406656
[TBL] [Abstract][Full Text] [Related]
10. Clinical and molecular characteristics of Chinese non-small cell lung cancer patients with ERBB2 transmembrane domain mutations.
Fan Y; Qiu J; Yu R; Cao R; Chen X; Ou Q; Wu X; Shao YW; Nagasaka M; Zhang J; Ou SI
Mol Oncol; 2020 Aug; 14(8):1731-1739. PubMed ID: 32478891
[TBL] [Abstract][Full Text] [Related]
11. LncRNA TMPO-AS1 facilitates the proliferation and metastasis of NSCLC cells by up-regulating ERBB2 via sponging miR-204-3p.
Yu X; Lin Q; Liu F; Yang F; Mao J; Chen X
Int J Immunopathol Pharmacol; 2020; 34():2058738420958947. PubMed ID: 32969763
[TBL] [Abstract][Full Text] [Related]
12. Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer.
Wei XW; Gao X; Zhang XC; Yang JJ; Chen ZH; Wu YL; Zhou Q
Thorac Cancer; 2020 Jun; 11(6):1512-1521. PubMed ID: 32291971
[TBL] [Abstract][Full Text] [Related]
13. Autocrine activation of ErbB2/ErbB3 receptor complex by NRG-1 in non-small cell lung cancer cell lines.
Gollamudi M; Nethery D; Liu J; Kern JA
Lung Cancer; 2004 Feb; 43(2):135-43. PubMed ID: 14739033
[TBL] [Abstract][Full Text] [Related]
14. [Role of HER2 in NSCLC].
Zhang K; Wang H
Zhongguo Fei Ai Za Zhi; 2015 Oct; 18(10):644-51. PubMed ID: 26483338
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of pyrotinib for bone marrow metastasis induced pancytopenia in a patient with non-small-cell lung cancer and ERBB2 mutation.
Wu Y; Ni J; Chang X; Zhang X; Zhang L
Thorac Cancer; 2020 Jul; 11(7):2051-2055. PubMed ID: 32458584
[TBL] [Abstract][Full Text] [Related]
16. ERBB2 exon 20 insertions are rare in Brazilian non-small cell lung cancer.
de Oliveira Cavagna R; Zaniolo BG; de Paula FE; Berardinelli GN; Santana I; da Silva ECA; Dias JM; Jacinto AA; da Nóbrega Oliveira REN; de Marchi P; Leal LF; Reis RM
Thorac Cancer; 2022 Dec; 13(23):3402-3407. PubMed ID: 36251951
[TBL] [Abstract][Full Text] [Related]
17. Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea.
Lee K; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Cancer Res Treat; 2020 Jan; 52(1):292-300. PubMed ID: 31345011
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.
Suzawa K; Toyooka S; Sakaguchi M; Morita M; Yamamoto H; Tomida S; Ohtsuka T; Watanabe M; Hashida S; Maki Y; Soh J; Asano H; Tsukuda K; Miyoshi S
Cancer Sci; 2016 Jan; 107(1):45-52. PubMed ID: 26545934
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of c-erbB2 protein correlates with disease-stage and chromosomal gain at the c-erbB2 locus in non-small cell lung cancer.
Kristiansen G; Yu Y; Petersen S; Kaufmann O; Schlüns K; Dietel M; Petersen I
Eur J Cancer; 2001 Jun; 37(9):1089-95. PubMed ID: 11378338
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung.
Grob TJ; Kannengiesser I; Tsourlakis MC; Atanackovic D; Koenig AM; Vashist YK; Klose H; Marx AH; Koops S; Simon R; Izbicki JR; Bokemeyer C; Sauter G; Wilczak W
Mod Pathol; 2012 Dec; 25(12):1566-73. PubMed ID: 22899293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
